ClinicalTrials.gg
Active, not recruitingNCT02825134NOTION-2Updated Apr 9, 2024

Comparison of TAVR With SAVR in Younger Low Surgical Risk Patients With Severe Aortic Stenosis

An interventional study of Transcatheter aortic valve replacement and Surgical aortic valve replacement in Aortic Valve Stenosis, Cardiovascular Diseases and Heart Diseases, sponsored by Ole De Backer. Active, not recruiting at 9 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Ole De Backer · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
376
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Aortic Valve Stenosis with a site in Finland — 6 open to participants now, 15 under way, none of them phase 3. Aortic Valve Stenosis · Finland.

Enrollment
7th of 10
376 · median 443
Started
2016
with 1 other
No phase
8 of 27
2 open now
Primary completion
2024-02
later than 5 of 14 live
Registered
9th of 27
by date
Lead sponsor
2 of 27
Ole De Backer

Among the 27 studies in Aortic Valve Stenosis with a site in Finland, this one is the 7th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2016, is one of 8 with no phase, reaches primary completion later than 5 of the 14 other live ones, and was the 9th registered.

Aortic Valve Stenosis

1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

6 of the 27 studies in Aortic Valve Stenosis with a site in Finland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Finland have not opened yet or have stopped. Only those recruiting at a site in Finland →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Aortic Valve Stenosis with a site in Finland, or all of them as a file.
02

Study summary

A randomized clinical trial investigating transcatheter (TAVR) versus surgical (SAVR) aortic valve replacement in patients 75 years of age or younger suffering from severe aortic valve stenosis.

Study hypothesis: The clinical outcome (death of any cause, stroke and rehospitalization (related to the procedure, valve or heart failure)) obtained within one year after TAVR is non-inferior to SAVR.

Read the detailed description

BACKGROUND: Acquired aortic valve stenosis (AS) is the most common heart valve disease in the Western World with a prevalence of 2-7% at the age of >65 years. If untreated, it may lead to heart failure and death. Surgical aortic valve replacement (SAVR) until recent years has been the definitive treatment for patients with severe symptomatic AS. A less invasive transcatheter aortic valve replacement (TAVR) has been developed and has been a treatment of choice mostly for elderly high risk or inoperable patients. As TAVR technology is continuously evolving and improving, it may be anticipated that it will become a valuable alternative - and even the preferred choice of treatment - for younger, low-risk patients with severe aortic valve stenosis in the near future. However, to date, there is no clinical evidence that supports this hypothesis.

AIM: The purpose of the study is to compare TAVR and SAVR with regard to the intra- and post-procedural morbidity and mortality rate, hospitalization length, functional capacity, quality of life, and valvular prosthesis function in younger, low risk patients with severe bicuspid or tricuspid AS, scheduled for aortic valve replacement.

POPULATION: Younger low risk patients with severe aortic valve stenosis, which are scheduled for aortic valve replacement using a bioprosthesis. Subjects fulfilling the inclusion criteria, not having any exclusion criteria, and consenting to the trial will be randomized 1:1 to TAVR or SAVR with 186 patients in each group.

DESIGN: The study is a randomized clinical multicenter trial. Central randomization with variable block size and stratification by gender and coronary comorbidity will be used. An independent event committee blinded to treatment allocation will adjudicate safety endpoints.

INTERVENTIONS:

TAVR: Any CE-Mark approved transcatheter aortic bioprosthesis may be used in the study, and the choice is at the discretion of the local TAVR team. The transfemoral TAVR procedure may be performed under general anaesthesia, local anaesthesia/conscious sedation, or local anesthesia. Percutaneous coronary intervention (PCI) can be performed up to 30 days prior to TAVR or as a hybrid procedure.

SAVR: The surgical SAVR technique follows standard protocol of the local department of cardio-thoracic surgery. The operation is performed under general anesthesia, which follows standard protocol of the department of anesthesiology. A commercial available surgical aortic bioprosthesis at the surgeons discretion will be implanted. Concomitant coronary artery bypass graft (CABG) surgery may be performed.

END POINTS: The primary endpoint is the composite rate of death of any cause, stroke and rehospitalization (related to the procedure, valve or heart failure) within one year after the procedure. Secondary endpoints are listed below. Follow-up will be performed after 1 and 12 months and yearly thereafter for a minimum of 10 years.

03

Conditions studied

  • Aortic Valve Stenosis
  • Cardiovascular Diseases
  • Heart Diseases
  • Heart Valve Diseases
  • Ventricular Outflow Obstruction

Keywords

  • heart valve disease
  • valvular bioprosthesis
  • aortic valve replacement
  • Randomized clinical trial
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 75 years or younger.
  • Severe calcific AS (Valve area \<1cm2 (or \<0.6 cm2/m2) AND one of the two following criteria: mean gradient >40mmHg or peak jet velocity >4.0m/s, OR in presence of low flow, low gradient with reduced or normal \<50%, a dobutamine stress echo should verify true severe AS rather than pseudo-AS
  • Symptomatic with angina pectoris, dyspnea or exercise-induced syncope or near syncope OR asymptomatic with abnormal exercise test showing symptoms on exercise clearly related to AS or systolic LV dysfunction (LVEF \<50%) not due to another cause.
  • Anticipated usage of biological aortic valve prosthesis.
  • Low risk for conventional surgery (STS Score \<4%).
  • Suitable for both SAVR and transfemoral TAVR.
  • >1 year after the intervention.
  • to participate in the study after adequate information about the study before randomization and intervention.

Exclusion criteria

Exclusion Criteria:

  • Coronary artery disease, not suitable for both percutaneous coronary intervention (PCI) or coronary artery bypass graft surgery (CABG).
  • Coronary angiogram with a SYNTAX-score >22.
  • \<25% without contractile reserve during dobutamine stress echocardiography.
  • Porcelain aorta, which prevents open-heart surgery.
  • Bicuspid valve with aorta ascendens diameter ≥45mm
  • Severe femoral, iliac or aortic atherosclerosis, calcification, coarctation, aneurysm or tortuosity, which prevents transfemoral TAVR.
  • Need for open heart surgery other than SAVR with or without CABG.
  • Myocardial infarction within last 30 days
  • Stroke or within the last 30 days. NOTION-2, 01. February 2017, version 5 9
  • Current endocarditis, intracardiac tumor, thrombus or vegetation.
  • Ongoing severe infection requiring intravenous antibiotics.
  • Unstable pre-procedural condition requiring intravenous inotropes or mechanical assist device (IABP, Impella) on the day of intervention.
  • Kidney disease requiring dialysis or severely impaired lung function ( and/or diffusion capacity \<40% of predicted).
  • Allergy to heparin, iodid contrast agent, warfarin, aspirin or clopidogrel.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
376 participants (actual)

Study arms

  • Experimental
    Transcatheter aortic valve replacement

    Transcatheter aortic valve replacement

    Device: Transcatheter aortic valve replacement

  • Active comparator
    Surgical aortic valve replacement

    Surgical aortic valve replacement

    Device: Surgical aortic valve replacement

Interventions

  • DeviceTranscatheter aortic valve replacement

    Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.

    Also known as: Transcatheter aortic valve implantation, TAVR, TAVI

  • DeviceSurgical aortic valve replacement

    Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.

    Also known as: SAVR

06

What researchers measure

Primary outcomes

  1. Composite rate of all-cause mortality, stroke and rehospitalization (related to the procedure, the valve or heart failure) within one year after the procedure.

    VARC-3 definitions

    Time frame: at one year post-procedural.

Secondary outcomes

  1. Procedure time

    hours

    Time frame: Intraoperative

  2. Duration of index hospitalization

    days

    Time frame: Number of days from admission to discharge (expected an averge of 7 days)

  3. Composite rate of all-cause mortality, stroke and rehospitalization (related to the procedure, the valve or heart failure)

    VARC-3 definitions

    Time frame: at 1 month and yearly thereafter up to 10 years post-procedure

  4. Composite rate of all-cause mortality, disabling stroke and rehospitalization (related to the procedure, the valve or heart failure)

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  5. Rehospitalization both composite and individual of related to the procedure, the valve or heart failure)

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  6. Composite rate of all-cause mortality and disabling stroke

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  7. All-cause mortality

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  8. Cardiovascular mortality

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  9. Non-cardiovascular mortality

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  10. Stroke

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  11. Disabling Stroke

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  12. Non-disabling stroke

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  13. Transient Ischemic attack

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  14. Myocardial Infarction

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  15. Endocarditis

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  16. Valve Thrombosis

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  17. Need for aortic valve re-intervention

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  18. Bleeding (life-threatening or major)

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  19. Vascular complication (major)

    VARC-3 defintions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  20. Acute kidney injury (stage 2 or 3)

    VARC-3 defintions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  21. Echocardiographic aortic bioprosthesis performance (degree of paravalvular leakage, valve area, mean gradient, prosthesis patient mismatch)

    VARC-3 definitions

    Time frame: at discharge, 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  22. NYHA functional class

    NYHA functional class

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  23. Need for permanent pacemaker

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  24. New onset atrial fibrillation captured on ECG

    VARC-3 definitions

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  25. Left ventricle remodeling as assesed by echocardiography

    Left ventricle internal diameter in diastoli

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

  26. Quality of life change from baseline

    Kansas City Cardiomyopathy Questionnaire, scale 0 (worse) to 100 (better)

    Time frame: at 1 and 12 months, and yearly thereafter up to 10 years post-procedure

07

Study locations

9 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Feb 2024, 92 months.

Of 177 non-industry interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 79. This study's 92 months is above that.

Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2016
First posted
Jul 7, 2016
StartActual
Jun 30, 2016
Primary completionActual
Feb 2024
CompletionEst.
Jun 2029
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02825134
Lead sponsor
Ole De Backer
Responsible party
Ole De Backer (MD, PhD, Rigshospitalet, Denmark) — Sponsor-investigator
First posted
Jul 7, 2016
Start date
Jun 30, 2016
Primary completion
Feb 2024
Completion
Jun 2029 (estimated)
Last update
Apr 9, 2024

Study contacts

Ole De Backer, MD; PhD
principal investigator · Rigshospitalet, Denmark
Hans GH Thyregod, MD, PhD
principal investigator · Rigshospitalet, Denmark

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion